Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Asset Writedowns and Impairment (2016 - 2026)

Anika Therapeutics has reported Asset Writedowns and Impairment over the past 17 years, most recently at $111000.0 for Q1 2026.

  • Quarterly Asset Writedowns and Impairment fell 86.66% to $111000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$721000.0 through Mar 2026, up 96.61% year-over-year, with the annual reading at $195000.0 for FY2024, 94.16% down from the prior year.
  • Asset Writedowns and Impairment was $111000.0 for Q1 2026 at Anika Therapeutics, up from -$5.0 million in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $3.1 million in Q3 2024 and troughed at -$25.9 million in Q4 2024.
  • The 5-year median for Asset Writedowns and Impairment is $207500.0 (2022), against an average of -$1.0 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 1922.55% in 2024 against a maximum downside of 966.23% in 2024.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at -$448000.0 in 2022, then soared by 766.96% to $3.0 million in 2023, then tumbled by 966.23% to -$25.9 million in 2024, then soared by 80.8% to -$5.0 million in 2025, then surged by 102.23% to $111000.0 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Asset Writedowns and Impairment are $111000.0 (Q1 2026), -$5.0 million (Q4 2025), and $1.1 million (Q3 2025).